{
"id":"mk19_a_id_t64",
"number":64,
"bookId":"id",
"title":{
"__html":"Prophylaxis against Opportunistic Infections in HIV/AIDS"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"022e4e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 64. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t64"
}
]
},
"Prophylaxis against Opportunistic Infections in HIV/AIDS"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6988a3",
"class":"col hd l",
"children":[
"Opportunistic Infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"92335c",
"class":"col hd l",
"children":[
"Preferred Drug"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f1a56",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis jirovecii"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25b570",
"class":"cell txt l",
"children":[
"CD4 cell count <200/µL",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f1664",
"class":"cell txt l",
"children":[
"TMP-SMX, double-strength or single-strength tablet once daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e82db4",
"class":"cell txt l",
"children":[
"Toxoplasmosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64449b",
"class":"cell txt l",
"children":[
"CD4 cell count <100/µL and positive serologic results",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6201a3",
"class":"cell txt l",
"children":[
"TMP-SMX, double-strength tablet once daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad7577",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium avium"
]
},
" complex"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3a376",
"class":"cell txt l",
"children":[
"CD4 cell count <50/µL",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9016b8",
"class":"cell txt l",
"children":[
"Azithromycin, 1200 mg once weekly or 600 mg twice weekly; clarithromycin, 500 mg twice daily"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"efb001",
"class":"cell txt l",
"children":[
"Latent tuberculosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c01346",
"class":"cell txt l",
"children":[
"TST >5 mm or positive IGRA results"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b7058",
"class":"cell txt l",
"children":[
"3 months of isoniazid plus rifapentine given once weekly"
]
},
" ",
{
"type":"p",
"hlId":"3619db",
"class":"cell txt l",
"children":[
"3 months of isoniazid plus rifampin given daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IGRA = interferon-γ release assay; TMP-SMX = trimethoprim-sulfamethoxazole; TST = tuberculin skin test."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Prophylaxis may be discontinued in patients with CD4 cell count ≥200/µL for ≥3 months; emerging evidence suggests prophylaxis may be discontinued in patients with CD4 cell count of 100-200/µL and a suppressed viral load for ≥3 months."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Alternatives for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis jirovecii"
]
},
" prophylaxis may be found here: ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/321/pneumocystis-pneumonia",
"target":"_blank"
},
"children":[
"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/321/pneumocystis-pneumonia"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Alternatives for toxoplasmosis prophylaxis may be found here: ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/322/toxoplasma-gondii",
"target":"_blank"
},
"children":[
"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/322/toxoplasma-gondii"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Prophylaxis no longer recommended in patients who start antiretroviral therapy immediately."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Drug interactions with first-line antiretroviral therapy regimens (including tenofovir alafenamide, integrase inhibitors) are common, and HIV or latent tuberculosis regimens may need to be modified. Daily pyridoxine is recommended in patients who will receive isoniazid because of the risk for peripheral neuropathy. See ",
{
"type":"cross-reference",
"target":"mk19_a_id_s6_5_1",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" Infection"
]
},
" for dosing information. Other organizations may include additional recommended regimens. Recommendations from Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69:1-11. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32053584",
"target":"_blank"
},
"children":[
"PMID: 32053584"
]
},
" doi:10.15585/mmwr.rr6901a1"
]
]
}